Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma

By Torsten O. Nielsen, Forrest D. Hsu, Kristin Jensen, Maggie C. U. Cheang, G. Karaca, Zhiyuan Hu, Tina Hernandez-Boussard, C. Livasy, D. Cowan, L. Dressler and 6 more. Clinical Cancer Research, 2004

2,689 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/049b7625662f20d4f9199006079ac636fa8db905

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Oncology

In Pathology and Forensic Medicine

Citations in the corpus

An overview of triple-negative breast cancer (2016, background): “TNBC detected by IHC are EGFR, cKIT, cytokeratins 5/6, 14 and 17, p53, p15 and cyclin E [5] and are associated”
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors (2007, background): “As described above, the Brca1+/-;p53+/-;IR, some Brca1Co/Co;TgMMTV-Cre;p53+/, DMBA-induced, and TgMMTV-Wnt1 tumors stained positive for K5 by IF, and human basal-like tumors tend to stain positive using a K5/6 antibody [1,12,18,26], thus showing that basal-like tumors from both species share K5 prot”
BRCA1 dysfunction in sporadic basal-like breast cancer (2007, methodology): “Basal-like cancers only infrequently express the oestrogen or progesterone receptor and rarely overexpress HER2 (Nielsen et al., 2004).”
The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes (2007, neutral): “markers could be used for molecular subtyping (6).”
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. (2006, methodology): “, 2004] using published gene markers of in vivo histology (Abd El-Rehim et al., 2004; Cattoretti et al., 1988; Jones et al., 2004; Korsching et al., 2002; Nielsen et al., 2004; Simpson et al., 2004).”
Triple-negative breast cancer molecular subtyping and treatment progress (2020, background): “The MSL subtype overexpresses angiogenesisrelated receptors PDGFR and VEGFR, which might make them susceptible to antiangiogenic therapy.”
An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors (2008, background): “Basal-like tumors are mostly grade 3 and lack expression of the estrogen receptor, possessing a high proliferation rate and a high nucleus-to-cytoplasm volume rati”
Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. (2008, positive): “This classification has also been reproduced to a certain extent in immunohistochemical studies (5, 6).”
Molecular classification and molecular forecasting of breast cancer: ready for clinical application? (2005, background): “Importantly a very similar classification of breast cancers has now been characterized using immunohistochemistry to analyze patterns of protein expression in tumor sections and suggesting that a few protein biomarkers (eg, ER, progesterone receptor [PR], HER2, HER1, basal cytokeratins) can be used ”
BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. (2010, background): “, 2010) (including both luminal and basal subtypes defined according to Nielsen’s criteria) (Nielsen et al., 2004) and in the NKI295 tumor gene expression data set (Table 1; Table S5; van de Vijver et al.”
Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. (2011, methodology): “In addition, recognition that finer tumor classification using expanded marker panels in addition to ER and PR may reveal greater heterogeneity (1), heightens the need for large datasets.”